State of AI in Science & Research 2026

Artificial intelligence has shifted from a research curiosity to core scientific infrastructure: AlphaFold has predicted over 200 million protein structures used by more than two million researchers, and AI breakthroughs swept the 2024 Nobel Prizes. Surging private investment in generative AI and a steep rise in FDA-cleared AI medical devices show the same momentum moving from the lab into regulated, real-world use.

AlphaFold redefined the scale of discovery

DeepMind's AlphaFold predicted the structures of over 200 million proteins, effectively covering nearly all catalogued proteins known to science. More telling than the count is the reach: the AlphaFold database has been used by more than two million researchers across over 190 countries. This is what mature scientific AI looks like, not a demo but shared infrastructure that other labs build upon daily. The breadth of adoption, including in low- and middle-income countries, helps democratize structural biology that once required costly experimental methods.

AI now wins science's highest honors

In 2024, AI-driven research received top recognition when Demis Hassabis and John Jumper shared the Nobel Prize in Chemistry for protein-structure prediction, and deep-learning pioneers were honored in physics. This is a turning point: prizes traditionally reward decades-old foundational work, so honoring AI methods signals the scientific establishment now treats them as legitimate engines of discovery. We read it as validation that AI is not merely accelerating existing science but enabling results that were previously out of reach. That endorsement tends to pull funding and talent toward AI-native research programs.

Investment and databases expand together

Generative AI attracted $33.9 billion in private investment worldwide in 2024, up 18.7% on the prior year, according to Stanford's AI Index. That capital is visible in the data layer of science: since 2021, entries in major protein databases grew sharply, with the AlphaFold database expanding 585% and UniProt up 31%. The pattern is reinforcing, as better models generate more structures, which seed more research, which justifies more funding. For research-tool builders, the signal is durable demand for AI that produces and curates scientific data, not just chats about it.

Regulators are catching up to the lab

The translation from research to practice is clearest in medicine, where the FDA had authorized 223 AI-enabled medical devices by 2023, up from only six as recently as 2015. In parallel, 2024 saw a wave of large medical foundation models such as Med-Gemini alongside specialist systems for radiology and cardiology. Regulatory throughput is becoming a real constraint and enabler rather than a footnote. We expect approval volumes to keep rising as evaluation frameworks for clinical AI mature, pulling more research-stage models into deployment.

Häufige Fragen

More reports

Compiled by ToolGlance from publicly reported data; figures link to their sources. Updated 2026-05-30.